Stay updated with breaking news from Global Program Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from open-label extension period of the Phase 2 trial demonstrate that longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms Data
Board expansion brings significant additional gene therapy and corporate development expertise to AnjariumZURICH, Oct. 18, 2022 /PRNewswire/ -- Anjarium Biosciences AG ("Anjarium"), a biotech
- Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities- Company recently initiated clinical trial of...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb 1, 2022--
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.